iRGD-guided tumor-penetrating nanocomplexes for therapeutic siRNA delivery to pancreatic cancer
Lo JH, Hao L, Muzumdar MD, Raghavan S, Kwon EJ, Pulver EM, Hsu F, Aguirre AJ, Wolpin BM, Fuchs CS, Hahn WC, Jacks T, Bhatia SN. iRGD-guided tumor-penetrating nanocomplexes for therapeutic siRNA delivery to pancreatic cancer. Molecular Cancer Therapeutics 2018, 17: molcanther.1090.2017. PMID: 30097486, PMCID: PMC6298224, DOI: 10.1158/1535-7163.mct-17-1090.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic cancerCancer-related deathReceptor expression patternsSite of diseasePDAC cell linesMol Cancer TherTherapeutic trialsAutochthonous tumorsDuctal adenocarcinomaMouse modelStromal barrierTumor growthSystemic deliveryNeuropilin-1Peptide iRGDTumor-penetrating abilityThree-dimensional organoidsSiRNATumor targetingCell linesTherapyCancerStromaIRGDDifferences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer
Tao Z, Muzumdar MD, Detappe A, Huang X, Xu ES, Yu Y, Mouhieddine TH, Song H, Jacks T, Ghoroghchian PP. Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. Nano Letters 2018, 18: 2195-2208. PMID: 29533667, PMCID: PMC5957485, DOI: 10.1021/acs.nanolett.7b04043.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaHuman pancreatic ductal adenocarcinomaPancreatic tumorsMouse modelAutochthonous modelPoor overall prognosisAutochthonous mouse modelAutochthonous tumor modelTumor cell clustersOverall prognosisSurvival outcomesPancreatic cancerDuctal adenocarcinomaTransplanted tumorPreclinical studiesFree drug formulationDense stromaPreclinical testingTumor modelTumorsOxaliplatinNoninvasive optical imagingAnticancer agentsAnticancer drugsTherapeutic formulations